Enteroporc Coli AC


Neonatal piglet colibacillosis (recombinant, inactivated) / Clostridium perfringens vaccine (inactivated)

This medicine is authorised for use in the European Union.


Enteroporc Coli AC is a veterinary vaccine given to sows (female pigs that have already given birth to piglets) or gilts (female pigs that have not yet given birth to piglets) to protect their offspring from intestinal disease caused by the bacteria Escherichia coli (E. coli) and Clostridium perfringens (C. perfringens) types A and C. It contains parts of the E. coli bacterium called fimbrial adhesins F4ab, F4ac, F5 and F6 and of the C. perfringens bacterium called alfa, beta1 and beta2 toxoids (inactivated toxins).

This EPAR was last updated on 24/09/2021

Authorisation details

Product details
Enteroporc Coli AC
Agency product number
Active substance
CLOSTRIDIUM PERFRINGENS TYPE C, BETA1 TOXOID / Clostridium perfringens, type A, alpha toxoid / Clostridium perfringens, type A, beta2 toxoid / Escherichia coli, fimbrial adhesin F4ab / Escherichia coli, fimbrial adhesin F4ac / Escherichia coli, fimbrial adhesin F5 / Escherichia coli, fimbrial adhesin F6
International non-proprietary name (INN) or common name
  • Neonatal piglet colibacillosis (recombinant, inactivated)
  • Clostridium perfringens vaccine (inactivated)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
CEVA Santé Animale
Date of issue of marketing authorisation valid throughout the European Union
Contact address

10 avenue de La Ballastière
33500 Libourne

Product information

28/04/2021 Enteroporc Coli AC - EMEA/V/C/005149 - IAIN/0004-G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for suidae

  • Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium

Therapeutic indication

For the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:
-           Clinical signs (severe diarrhoea) and mortality caused by Escherichia coli strains expressing the fimbrial adhesins F4ab, F4ac, F5 and F6
-           Clinical signs (diarrhoea during the first days of life) associated with Clostridium perfringens type A expressing alpha and beta 2 toxins
-           Clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by Clostridium perfringens type C expressing beta1 toxin

Assessment history

How useful was this page?

Add your rating